EMPFIELD JAMES R. 4
4 · Xenon Pharmaceuticals Inc. · Filed Aug 16, 2022
Insider Transaction Report
Form 4
EMPFIELD JAMES R.
SVP, Drug Discovery
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2022-08-12−45,000→ 0 totalExercise: $4.75Exp: 2028-03-11→ Common Shares (45,000 underlying) - Exercise/Conversion
Common Shares
2022-08-12$4.75/sh+45,000$213,750→ 75,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-08-12−20,000→ 0 totalExercise: $3.10Exp: 2027-10-22→ Common Shares (20,000 underlying) - Exercise/Conversion
Common Shares
2022-08-12$3.10/sh+20,000$62,000→ 30,000 total - Tax Payment
Common Shares
2022-08-12$38.02/sh−7,257$275,911→ 67,743 total - Sale
Common Shares
2022-08-12$38.08/sh−35,868$1,365,853→ 31,875 total - Sale
Common Shares
2022-08-12$38.68/sh−21,875$846,125→ 10,000 total
Footnotes (4)
- [F1]Represents the closing price of the Company's common shares on August 11, 2022 for purposes of net settlement calculations.
- [F2]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.5101 to $38.5029, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.6084 to $38.7884, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]The shares subject to the option are fully vested and exercisable.